Search
Vaccination has been a cornerstone of public health, substantially reducing the global burden of infectious diseases, notably evident during the COVID-19 pandemic caused by SARS-CoV-2.
Respiratory syncytial virus (RSV) is a leading cause of acute lower respiratory tract infection in young children and the second leading cause of infant death worldwide. While global circulation has been extensively studied for respiratory viruses such as seasonal influenza, and more recently also in great detail for SARS-CoV-2, a lack of global multi-annual sampling of complete RSV genomes limits our understanding of RSV molecular epidemiology.
Anthony Kicic BSc (Hons) PhD Rothwell Family Fellow; Head, Airway Epithelial Research Anthony.Kicic@thekids.org.au Rothwell Family Fellow; Head,
SARS-CoV-2 nucleocapsid (N) protein antibodies can be used to identify the serological response to natural infection in those who have previously received a COVID-19 spike-based vaccine. Anti-N antibody responses can also be induced by inactivated whole SARS-CoV-2 virus vaccines, such as CoronaVac. We aimed to characterise antibody responses to the N protein following COVID-19 and following vaccination with CoronaVac.
Respiratory syncytial virus (RSV) remains a leading cause of mortality and morbidity worldwide. RSV seasonality was disrupted by COVID-19-associated nonpharmaceutical interventions (NPIs). We review RSV seasonality, molecular epidemiology, clinical manifestations, and community awareness to inform future prevention strategies.
The global invasive meningococcal disease (IMD) landscape changed considerably during the COVID-19 pandemic, as evidenced by decreased incidence rates due to COVID-19 mitigation measures, such as limited social contact, physical distancing, mask wearing, and hand washing. Vaccination rates were also lower during the pandemic relative to pre-pandemic levels.
Perth researchers are leading an international clinical trial focused on preventing the spread of COVID-19 by testing the effectiveness of the drug interferon in reducing the infectiousness of people who contract the virus.
Top infectious disease experts in Australia will lead a clinical trial to determine whether combining different Covid-19 vaccines in the nation’s booster immunisation will increase effectiveness.
A study of ORIGINS families has revealed a positive aspect to the COVID pandemic, with families found to benefit from the extra time together during lockdowns and mobile devices proving useful for helping them stay in touch with extended family and friends and for activities such as online classes.
As the world waits for a COVID-19 vaccine Perth researchers are getting one step ahead – embarking on a new study designed to prepare parents and government for a potential Australia-wide vaccination program.